Molecular analyses of imatinib-resistant GIST have demonstrated that secondary KIT mutations arise predominantly within the ATP-binding pocket (exons 13 and 14) or the activation loop (exons 17 and 18), with these distinct alterations differentially affecting sensitivity to subsequent TKIs [44,45]. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.